aibioVyome names Jerry Leonard chief financial officer
Tickers HIND
The board appointed Jerry Leonard as chief financial officer on August 27, 2026, effective September 1, 2026, under a consulting agreement with ClearbridgeCFO, LLC, after interim CFO Robert Dickey gave notice of his resignation.
Key facts
- Company
- Vyome Holdings, Inc. (NASDAQ: HIND)
- News type
- Company Updates
- Primary source
- Vyome Holdings, Inc. 8-K (2026-08-28)
Vyome Holdings, Inc. appointed Jerry Leonard as its chief financial officer, according to a Form 8-K filed August 28, 2026. The board made the appointment on August 27, 2026, reported under Item 5.02. Mr. Leonard will serve as the company's principal financial officer and principal accounting officer effective September 1, 2026.
The same filing says Robert Dickey notified the board on August 25, 2026 of his intention to resign as interim chief financial officer, effective August 31, 2026. The filing says the resignation was not the result of any disagreement with the company on any matter relating to its operations, policies or practices. The consulting agreement with Foresite Advisors, LLC, dated August 26, 2024, will be deemed terminated as of August 31, 2026.
The consulting terms
Mr. Leonard will be assigned to the company by ClearbridgeCFO, LLC, a Georgia limited liability company, under a Consulting Agreement dated August 27, 2026 among the company, ClearbridgeCFO and Mr. Leonard. The company will pay ClearbridgeCFO a consulting fee of $15,000 per calendar month. The initial term is one year, renewing automatically for 12-month periods.
Either party may end the agreement for cause on 15 days' prior written notice, or without cause on 60 days' prior written notice. The company may end it at once if no acceptable replacement is provided within 30 days after Mr. Leonard stops being available.
The filing discloses no arrangements behind his selection and no related-party transactions.
Mr. Leonard's background
The filing describes Mr. Leonard as age 58 and the founder and chief executive officer of ClearbridgeCFO, an Atlanta-based fractional CFO and financial transformation firm. Since March 2026 he has served as fractional chief financial officer and secretary of VSee Health, a telehealth company, under an assignment through ClearbridgeCFO. From June 2024 to March 2026 he was senior vice president, chief financial officer and secretary of VSee Health.
Before that he was vice president of finance from 2010 to June 2021 at Voya Financial, Inc. The filing says he is a Certified Public Accountant with an MBA from Emory University.
What Vyome does
The company was renamed Vyome Holdings, Inc. after its merger with Vyome Therapeutics, Inc. on August 15, 2025. Its annual report on Form 10-K, filed March 18, 2026, describes it as a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need.
Its lead program, VT-1953, is a topical gel being developed to treat signs and symptoms of malignant fungating wounds in advanced cancer. The 10-K says the company has announced positive results from a phase 2 investigator-initiated trial, and it gives no numbers for them. Discussions with the Food & Drug Administration on a pivotal phase 3 design were only planned for the first half of 2026. The filing also names VT-1908, for steroid-sparing anterior uveitis, and VB1953, for moderate to severe acne, which it says is Phase 3-ready.
Financial position
The company's financial data show revenue of $319,714 for fiscal 2025, compared with $256,944 for fiscal 2024. Research and development expense was $588,258 in 2025, against $285,391 in 2024. The company reported a net loss of $10.3 million for 2025, compared with $1.4 million for 2024. Cash used in operations was $3.7 million in 2025 and $614,136 in 2024.
Year-end cash and cash equivalents were $5.0 million for 2025, according to a quarterly report on Form 10-Q filed August 12, 2026, compared with $101,904 at the end of 2024. The same data give $7.9 million at June 30, 2026, from the 10-Q.
The finance chief is again an outside consultant, billed monthly through a firm that also serves VSee Health, and either side can end the deal on 60 days' notice without cause. An interim CFO resigned and a consultant stepped in within days. The company reported a net loss of $10.3 million against revenue of $319,714, and its only marketed products are a dandruff lotion and shampoo in India. Its lead drug has no pivotal trial under way, and the 10-K warns that clinical delays raise costs and push back any revenue.